View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Oximio SMO Group
August 16, 2012

Oncolytics completes enrolment in UK Phase I cancer trial

Oncolytics Biotech, a Calgary-based biotechnology company, has completed patient enrolment in a UK Phase I clinical trial investigating Reolysin in combination with cyclophosphamide in patients with advanced malignancies. Reolysin is the company's proprietary formulation of the human reovirus.

Oncolytics Biotech, a Calgary-based biotechnology company, has completed patient enrolment in a UK Phase I clinical trial investigating Reolysin in combination with cyclophosphamide in patients with advanced malignancies. Reolysin is the company’s proprietary formulation of the human reovirus.

The study has enrolled patients diagnosed with advanced or metastatic solid tumours, including pancreatic, lung and ovarian cancers that are refractory to standard therapy, or for which no standard curative therapy exists.

Oncolytics chief operating officer Dr Matt Coffey said the company has completed the enrolment of the technical study examining cyclophosphamide’s potential to modulate the immune system’s response to Reolysin.

"Studies of this type help to advance our understanding of the interaction between the immune system and our product," Dr Coffey said.

The primary objective of the open-label study is to determine the minimum effective immunomodulatory dose of cyclophosphamide necessary to obtain successful immune modulation.

The secondary objectives of the dose-escalating, 36-patient trial include assessing the safety profile of the combination and gathering any evidence of antitumor activity.

Oncolytics’ clinical programme includes a variety of other human trials including a Phase III trial in head and neck cancers using Reolysin.

 

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU